Real-World Outcome and Prognostic Factors Among HER2-Positive Metastatic Breast Cancer Patients Receiving Pyrotinib-Based Therapy: A Multicenter Retrospective Analysis

References

• Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33. doi:10.3322/caac.21708
   PubMed Web of Science ®Google Scholar
• Hosonaga M, Arima Y, Sampetrean O, et al. HER2 heterogeneity is associated with poor survival in HER2-positive breast cancer. Int J Mol Sci. 2018;19:8. doi:10.3390/ijms19082158
   Web of Science ®Google Scholar
• Modi S, Saura C, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2020;382(7):610–621. doi:10.1056/NEJMoa1914510
   PubMed Web of Science ®Google Scholar
• Schlam I, Swain SM. HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now. NPJ Breast Cancer. 2021;7(1):56. doi:10.1038/s41523-021-00265-1
   PubMed Web of Science ®Google Scholar
• Yan M, Bian L, Hu X, et al. Pyrotinib plus capecitabine for human epidermal growth factor receptor 2-positive metastatic breast cancer after trastuzumab and taxanes (PHENIX): a randomized, double-blind, placebo-controlled Phase 3 study. Transl Breast Cancer Res. 2020;1:13. doi:10.21037/tbcr-20-25
   Google Scholar
• Xu B, Yan M, Ma F, et al. Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22(3):351–360. doi:10.1016/S1470-2045(20)30702-6
   PubMed Web of Science ®Google Scholar
• Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783–1791. doi:10.1056/NEJMoa1209124
   PubMed Web of Science ®Google Scholar
• Cortes J, Kim SB, Chung WP, et al. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N Engl J Med. 2022;386(12):1143–1154. doi:10.1056/NEJMoa2115022
   PubMed Web of Science ®Google Scholar
• Murthy RK, Loi S, Okines A, et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med. 2020;382(7):597–609. doi:10.1056/NEJMoa1914609
   PubMed Web of Science ®Google Scholar
• Johnston SRD, Hegg R, Im SA, et al. Phase III, randomized study of dual human epidermal growth factor receptor 2 (HER2) blockade with lapatinib plus trastuzumab in combination with an aromatase inhibitor in postmenopausal women with HER2-positive, hormone receptor-positive metastatic breast cancer: ALTERNATIVE. J Clin Oncol. 2018;36(8):741–748. doi:10.1200/JCO.2017.74.7824
   PubMed Web of Science ®Google Scholar
• Li C, Bian X, Liu Z, et al. Effectiveness and safety of pyrotinib-based therapy in patients with HER2-positive metastatic breast cancer: a real-world retrospective study. Cancer Med. 2021;10(23):8352–8364. doi:10.1002/cam4.4335
   PubMed Web of Science ®Google Scholar
• Chen Q, Ouyang D, Anwar M, et al. Effectiveness and safety of pyrotinib, and association of biomarker with progression-free survival in patients with HER2-positive metastatic breast cancer: a real-world, multicentre analysis. Front Oncol. 2020;10:811. doi:10.3389/fonc.2020.00811
   PubMed Web of Science ®Google Scholar
• Goksu SS, Bozcuk H, Koral L, et al. Factors predicting lapatinib efficacy in HER-2+ metastatic breast carcinoma: does it work better in different histologic subtypes? Indian J Cancer. 2015;52(4):517–519. doi:10.4103/0019-509X.178382
   PubMed Web of Science ®Google Scholar
• Montemurro F, Delaloge S, Barrios CH, et al. Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial. Ann Oncol. 2020;31(10):1350–1358. doi:10.1016/j.annonc.2020.06.020
   PubMed Web of Science ®Google Scholar
• Bartsch R, Berghoff AS, Furtner J, et al. Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, Phase 2 trial. Nat Med. 2022;28(9):1840–1847. doi:10.1038/s41591-022-01935-8
   PubMed Web of Science ®Google Scholar
• Bachelot T, Romieu G, Campone M, et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol. 2013;14(1):64–71. doi:10.1016/S1470-2045(12)70432-1
   PubMed Web of Science ®Google Scholar
• Saura C, Oliveira M, Feng YH, et al. Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with >/= 2 HER2-directed regimens: phase III NALA trial. J Clin Oncol. 2020;38(27):3138–3149. doi:10.1200/JCO.20.00147
   PubMed Web of Science ®Google Scholar
• Lin NU, Borges V, Anders C, et al. Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial. J Clin Oncol. 2020;38(23):2610–2619. doi:10.1200/JCO.20.00775
   PubMed Web of Science ®Google Scholar
• Yan M, Ouyang Q, Sun T, et al. Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): a multicentre, single-arm, two-cohort, phase 2 trial. Lancet Oncol. 2022;23(3):353–361. doi:10.1016/S1470-2045(21)00716-6
   PubMed Web of Science ®Google Scholar
• Gao M, Fu C, Li S, et al. The efficacy and safety of pyrotinib in treating HER2-positive breast cancer patients with brain metastasis: a multicenter study. Cancer Med. 2022;11(3):735–742. doi:10.1002/cam4.4481
   PubMed Web of Science ®Google Scholar
• Lin Y, Lin M, Zhang J, et al. Real-world data of pyrotinib-based therapy in metastatic HER2-positive breast cancer: promising efficacy in lapatinib-treated patients and in brain metastasis. Cancer Res Treat. 2020;52(4):1059–1066. doi:10.4143/crt.2019.633
   PubMed Web of Science ®Google Scholar
• Ma F, Ouyang Q, Li W, et al. Pyrotinib or lapatinib combined with capecitabine in HER2-positive metastatic breast cancer with prior taxanes, anthracyclines, and/or trastuzumab: a randomized, phase II study. J Clin Oncol. 2019;37(29):2610–2619. doi:10.1200/JCO.19.00108
   PubMed Web of Science ®Google Scholar
• Anwar M, Chen Q, Ouyang D, et al. Pyrotinib treatment in patients with HER2-positive metastatic breast cancer and brain metastasis: exploratory final analysis of real-world, multicenter data. Clin Cancer Res. 2021;27(16):4634–4641. doi:10.1158/1078-0432.CCR-21-0474
   PubMed Web of Science ®Google Scholar
• Rubovszky G, Budai B, Ganofszky E, et al. Predictive value of early skin rash in cetuximab-based therapy of advanced biliary tract cancer. Pathol Oncol Res. 2018;24(2):237–244. doi:10.1007/s12253-017-0238-y
   PubMed Web of Science ®Google Scholar
• Bettinger D, Schultheiss M, Knuppel E, Thimme R, Blum HE, Spangenberg HC. Diarrhea predicts a positive response to sorafenib in patients with advanced hepatocellular carcinoma. Hepatology. 2012;56(2):789–790. doi:10.1002/hep.25637
   PubMed Web of Science ®Google Scholar
• Wen HN, Liu YX, Xu D, Zhao KJ, Jiao Z. Population pharmacokinetic modeling of pyrotinib in patients with HER2-positive advanced or metastatic breast cancer. Eur J Pharm Sci. 2021;159:105729. doi:10.1016/j.ejps.2021.105729
   PubMed Web of Science ®Google Scholar
• Tamura R, Tanaka T, Akasaki Y, Murayama Y, Yoshida K, Sasaki H. The role of vascular endothelial growth factor in the hypoxic and immunosuppressive tumor microenvironment: perspectives for therapeutic implications. Med Oncol. 2019;37(1):2. doi:10.1007/s12032-019-1329-2
   PubMed Web of Science ®Google Scholar
• Yao JH, Shao Y, Wang JJ, et al. Evaluation of diagnostic and predictive values of the serum VEGF-A level and systemic immune-inflammation index in small cell lung cancer. J Cancer. 2021;12(5):1356–1364. doi:10.7150/jca.51972
   PubMed Web of Science ®Google Scholar
• Zhu Y, Guo M, Zhang L, Xu T, Wang L, Xu G. Biomarker triplet NAMPT/VEGF/HER2 as a de novo detection panel for the diagnosis and prognosis of human breast cancer. Oncol Rep. 2016;35(1):454–462. doi:10.3892/or.2015.4391
   PubMed Web of Science ®Google Scholar
• Su F, Geng J, Li X, et al. SP1 promotes tumor angiogenesis and invasion by activating VEGF expression in an acquired trastuzumab resistant ovarian cancer model. Oncol Rep. 2017;38(5):2677–2684. doi:10.3892/or.2017.5998
   PubMed Web of Science ®Google Scholar
• Rugo HS, Chien AJ, Franco SX, et al. A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer. Breast Cancer Res Treat. 2012;134(1):13–20. doi:10.1007/s10549-011-1918-z
   PubMed Web of Science ®Google Scholar